Secondary dyslipidemia refers to lipid abnormalities caused or exacerbated by underlying medical conditions, medications, or lifestyle factors. Identifying and addressing secondary causes is essential before attributing dyslipidemia to a primary (genetic or idiopathic) etiology and before intensifying lipid-lowering pharmacotherapy [1].
This clinic screens for secondary causes as part of the initial assessment (see 03 — Initial Assessment). Management of the underlying condition is the responsibility of the referring provider or appropriate specialist; this clinic manages the dyslipidemia component.
2.0 Systematic Screening Approach
The following conditions should be considered in every patient presenting with dyslipidemia, particularly when:
The lipid profile is disproportionate to the patient’s age and family history
Lipid abnormalities are new-onset or worsening without a clear explanation
The patient has a known condition associated with secondary dyslipidemia
3.0 Hypothyroidism
3.1 Mechanism
Hypothyroidism decreases LDL receptor expression and reduces hepatic cholesterol clearance, resulting in elevated LDL-C, total cholesterol, and sometimes triglycerides [2].
3.2 Lipid Pattern
Parameter
Typical Change
LDL-C
↑↑ (often significantly elevated)
Total cholesterol
↑↑
Triglycerides
↑ (modest)
HDL-C
↑ or unchanged
3.3 Screening and Action
Test
Threshold
Action
TSH
Elevated (> 4.5 mIU/L)
Refer to PCP or endocrinology for thyroid replacement therapy. Repeat lipid panel after TSH is normalized (typically 6–8 weeks after achieving euthyroid state). Defer lipid-lowering therapy intensification until thyroid is treated, unless the patient is at very high ASCVD risk.
Free T4
Low or low-normal
Supports diagnosis if TSH elevated
3.4 Subclinical Hypothyroidism
TSH 4.5–10 mIU/L with normal free T4
May contribute to mild LDL-C elevation
Thyroid replacement decision rests with the managing provider; this clinic monitors lipid impact
4.0 Diabetes Mellitus and Metabolic Syndrome
4.1 Diabetic Dyslipidemia Pattern
The characteristic lipid pattern of insulin resistance and type 2 diabetes [3]:
Parameter
Typical Change
Triglycerides
↑↑
HDL-C
↓↓
LDL-C
Variable (often normal or mildly elevated)
Small dense LDL
↑↑ (atherogenic)
ApoB
↑ (often discordant with LDL-C — more particles)
Non-HDL-C
↑
4.2 Clinical Implications
LDL-C may underestimate true atherogenic burden; ApoB and NMR LipoProfile are particularly valuable in this population (see 06 — Advanced Tools)
Diabetes is a PREVENT calculator input and independently increases ASCVD risk
Glycemic control improves triglycerides and modestly improves the overall lipid profile, but does not replace the need for LDL-C lowering therapy [1]
4.3 Action
Document diabetes and HbA1c as risk modifiers
Calculate PREVENT risk with diabetes input
Use ApoB to guide treatment intensity (LDL-C alone is unreliable in diabetic dyslipidemia)
Glycemic management is the responsibility of the referring provider
5.0 Chronic Kidney Disease (CKD)
5.1 Lipid Pattern in CKD
CKD Stage
Typical Pattern
Mild-moderate (eGFR 30–59)
↑ TG, ↓ HDL-C, variable LDL-C, ↑ small dense LDL
Severe (eGFR 15–29)
↑↑ TG, ↓↓ HDL-C, ↓ LDL-C (may be misleadingly low)
Nephrotic syndrome
↑↑↑ LDL-C, ↑↑↑ total cholesterol, ↑↑ TG
5.2 Nephrotic Syndrome
Nephrotic syndrome causes severe secondary hypercholesterolemia through increased hepatic lipoprotein synthesis and decreased catabolism [4].
Parameter
Typical Change
LDL-C
↑↑↑ (may exceed 300 mg/dL)
Total cholesterol
↑↑↑
Triglycerides
↑↑
Lipoprotein(a)
↑
5.3 Action
Document CKD stage and eGFR
eGFR is a PREVENT calculator input
CKD (eGFR 15–59) is a risk enhancer per 2026 guidelines [1]
Adjust drug dosing for renal function (especially fenofibrate, rosuvastatin)
Nephrotic syndrome: coordinate with nephrology; treat dyslipidemia aggressively but anticipate improvement with proteinuria reduction
6.0 Hepatic Disease
6.1 Steatotic Liver Disease (formerly NAFLD/NASH)
Parameter
Typical Change
Triglycerides
↑↑
HDL-C
↓
LDL-C
↑ or normal
Small dense LDL
↑
ALT/AST
May be elevated
Steatotic liver disease is a manifestation of metabolic syndrome
Statins are safe and indicated in patients with steatotic liver disease; they may even improve liver histology [5]
Mild ALT/AST elevation (< 3× ULN) is not a contraindication to statin therapy [1]
6.2 Cholestatic Liver Disease
May cause elevated LDL-C and lipoprotein X
Management of underlying liver disease takes priority; coordinate with hepatology
6.3 Cirrhosis
Advanced cirrhosis may cause low cholesterol levels due to impaired hepatic synthetic function
Low cholesterol in cirrhosis is a marker of disease severity, not a protective factor
7.0 Drug-Induced Dyslipidemia
The following medications commonly affect the lipid profile:
Cyclosporine also increases statin levels (drug interaction)
Atypical antipsychotics (olanzapine, clozapine)
↑
↑↑
↓
Weight gain and metabolic syndrome
Anabolic steroids / androgens
↑
↑
↓↓
Dramatic HDL-C reduction
Amiodarone
↑
—
—
Thyroid-mediated (may cause hypothyroidism)
Thiazide + beta-blocker combination
↑
↑
↓
Additive effects
7.1 Action
Document all medications known to affect lipid levels
Coordinate with prescribing provider regarding alternatives if the drug-induced dyslipidemia is clinically significant
Do not discontinue another provider’s medications without coordination
Treat the dyslipidemia according to the patient’s overall risk profile, accounting for the drug contribution
8.0 Lifestyle Factors
Factor
Lipid Effect
Notes
Excessive alcohol intake
↑↑ TG; ↑ HDL-C
Can cause severe hypertriglyceridemia (TG > 500); pancreatitis risk
Obesity
↑ TG; ↓ HDL-C; ↑ small dense LDL
Atherogenic dyslipidemia pattern
High-carbohydrate diet (> 60% calories)
↑ TG; ↓ HDL-C
Especially refined carbohydrates and sugars
Sedentary lifestyle
↑ TG; ↓ HDL-C
Exercise independently improves lipid profile
Anorexia nervosa
↑ LDL-C; ↑ total cholesterol
Paradoxical; due to decreased bile acid excretion and decreased LDL receptor activity
9.0 Other Medical Conditions
Condition
Lipid Effect
Notes
Polycystic ovary syndrome (PCOS)
↑ TG; ↓ HDL-C; ↑ small dense LDL
Insulin resistance driven
Cushing syndrome
↑ LDL-C; ↑ TG
Cortisol-mediated
Acromegaly
↑ TG
GH-mediated insulin resistance
Pregnancy
↑ LDL-C; ↑ TG (physiologic in 3rd trimester)
Statins contraindicated; manage conservatively
Obstructive liver disease / cholestasis
↑↑ LDL-C
Lipoprotein X; treat underlying cause
Glycogen storage diseases
↑↑ TG
Rare; manage underlying condition
10.0 Systematic Screening Checklist
At the initial assessment, screen for secondary causes using the following minimum evaluation:
Test / Assessment
Secondary Cause Screened
TSH
Hypothyroidism
HbA1c or fasting glucose
Diabetes
eGFR + UACR
CKD / nephrotic syndrome
Hepatic panel (ALT, AST)
Liver disease
Medication review
Drug-induced dyslipidemia
Alcohol history
Alcohol-induced hypertriglyceridemia
BMI
Obesity-associated dyslipidemia
If a secondary cause is identified, document it, notify or coordinate with the managing provider, and reassess the lipid profile after the secondary cause is addressed (where possible).
11.0 Version History
Version
Date
Description
1.0.0
2026-03-30
Initial release
References
2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026.
Duntas LH, Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am. 2012;96(2):269–281.
Taskinen MR, Boren J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239(2):483–495.
Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41–52.
Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. Metabolism. 2017;71:17–32.